2,364 Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,862 shares of the biopharmaceutical company’s stock after purchasing an additional 2,364 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $16,408,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in REGN. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth about $26,000. Armstrong Advisory Group Inc. boosted its stake in Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 28 shares during the last quarter. Activest Wealth Management boosted its stake in Regeneron Pharmaceuticals by 780.0% during the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 39 shares during the last quarter. Alpine Bank Wealth Management bought a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on REGN. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Sanford C. Bernstein upped their price objective on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a report on Friday, August 14th. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a “sector perform” rating in a research report on Thursday, October 8th. The Goldman Sachs Group raised their target price on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, JPMorgan Chase & Co. boosted their price target on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $847.90.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director directly owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,093 shares of company stock valued at $6,506,845. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.7%

Shares of NASDAQ REGN opened at $818.77 on Friday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12-month low of $591.52 and a 12-month high of $859.34. The firm’s 50-day moving average price is $791.28 and its 200-day moving average price is $737.25. The stock has a market capitalization of $84.30 billion, a price-to-earnings ratio of 20.87, a P/E/G ratio of 1.37 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the business posted $12.81 earnings per share. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.